BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Richards A, Kathryn Liszewski M, Kavanagh D, Fang CJ, Moulton E, Fremeaux-Bacchi V, Remuzzi G, Noris M, Goodship TH, Atkinson JP. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol 2007;44:111-22. [PMID: 16882452 DOI: 10.1016/j.molimm.2006.07.004] [Cited by in Crossref: 97] [Cited by in F6Publishing: 87] [Article Influence: 6.1] [Reference Citation Analysis]
Number Citing Articles
1 Schramm EC, Roumenina LT, Rybkine T, Chauvet S, Vieira-Martins P, Hue C, Maga T, Valoti E, Wilson V, Jokiranta S. Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. Blood. 2015;125:2359-2369. [PMID: 25608561 DOI: 10.1182/blood-2014-10-609073] [Cited by in Crossref: 79] [Cited by in F6Publishing: 67] [Article Influence: 11.3] [Reference Citation Analysis]
2 Frémeaux-Bacchi V, Arzouk N, Ferlicot S, Charpentier B, Snanoudj R, Dürrbach A. Recurrence of HUS due to CD46/MCP mutation after renal transplantation: a role for endothelial microchimerism. Am J Transplant. 2007;7:2047-2051. [PMID: 17617869 DOI: 10.1111/j.1600-6143.2007.01888.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
3 Bouts AH, Roofthooft MT, Salomons GS, Davin JC. CD46-associated atypical hemolytic uremic syndrome with uncommon course caused by cblC deficiency. Pediatr Nephrol 2010;25:2547-8. [PMID: 20652818 DOI: 10.1007/s00467-010-1609-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
4 Richards A, Kavanagh D, Atkinson JP. Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory statesthe examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration. Adv Immunol 2007;96:141-77. [PMID: 17981206 DOI: 10.1016/S0065-2776(07)96004-6] [Cited by in Crossref: 60] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
5 Thergaonkar RW, Narang A, Gurjar BS, Tiwari P, Puraswani M, Saini H, Sinha A, Varma B, Mukerji M, Hari P, Bagga A. Targeted exome sequencing in anti-factor H antibody negative HUS reveals multiple variations. Clin Exp Nephrol 2018;22:653-60. [PMID: 28939980 DOI: 10.1007/s10157-017-1478-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
6 Brocklebank V, Wong EK, Fielding R, Goodship TH, Kavanagh D. Atypical haemolytic uraemic syndrome associated with a CD46 mutation triggered by Shigella flexneri.. Clin Kidney J 2014;7:286-8. [PMID: 24944786 DOI: 10.1093/ckj/sfu032] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
7 Vaught AJ, Braunstein EM, Jasem J, Yuan X, Makhlin I, Eloundou S, Baines AC, Merrill SA, Chaturvedi S, Blakemore K, Sperati CJ, Brodsky RA. Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. JCI Insight 2018;3:99128. [PMID: 29563339 DOI: 10.1172/jci.insight.99128] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 11.5] [Reference Citation Analysis]
8 Frémeaux-Bacchi V, Fakhouri F, Roumenina L, Dragon-Durey MA, Loirat C. [Atypical hemolytic-uremic syndrome related to abnormalities within the complement system]. Rev Med Interne 2011;32:232-40. [PMID: 21376430 DOI: 10.1016/j.revmed.2009.09.039] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
9 Kavanagh D, Goodship TH. Atypical hemolytic uremic syndrome, genetic basis, and clinical manifestations. Hematology Am Soc Hematol Educ Program. 2011;2011:15-20. [PMID: 22160007 DOI: 10.1182/asheducation-2011.1.15] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 5.0] [Reference Citation Analysis]
10 Brocklebank V, Kavanagh D. Protecting the kidney from complement: atypical haemolytic uraemic syndrome. Clin Med (Lond) 2014;14 Suppl 6:s89-94. [PMID: 25468928 DOI: 10.7861/clinmedicine.14-6-s89] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
11 Wu H, Mao Z, Tan Y, Jiang Y, Yu J, Song L, Wu S, Sun M, Zhu L, Yu X, Zhang L, Yu F, Zhao MH. Genetic and functional analysis of two missense mutations in CD46 predispose to postpartum atypical hemolytic uremic syndrome. Clin Chim Acta 2020;503:61-9. [PMID: 31945341 DOI: 10.1016/j.cca.2020.01.009] [Reference Citation Analysis]
12 Yoshida Y, Kato H, Ikeda Y, Nangaku M. Pathogenesis of Atypical Hemolytic Uremic Syndrome. J Atheroscler Thromb 2019;26:99-110. [PMID: 30393246 DOI: 10.5551/jat.RV17026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
13 Garam N, Prohászka Z, Szilágyi Á, Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G, Bajcsi D, Brunner J, Dumfarth A, Cejka D, Flaschberger S, Flögelova H, Haris Á, Hartmann Á, Heilos A, Mueller T, Rusai K, Arbeiter K, Hofer J, Jakab D, Sinkó M, Szigeti E, Bereczki C, Janko V, Kelen K, Reusz GS, Szabó AJ, Klenk N, Kóbor K, Kojc N, Knechtelsdorfer M, Laganovic M, Lungu AC, Meglic A, Rus R, Kersnik-Levart T, Macioniene E, Miglinas M, Pawłowska A, Stompór T, Podracka L, Rudnicki M, Mayer G, Romana Rysava, Reiterova J, Saraga M, Tomáš Seeman, Zieg J, Sládková E, Szabó T, Capitanescu A, Stancu S, Tisljar M, Galesic K, Tislér A, Vainumäe I, Windpessl M, Zaoral T, Zlatanova G, Csuka D. C4 nephritic factor in patients with immune-complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy. Orphanet J Rare Dis 2019;14:247. [PMID: 31703608 DOI: 10.1186/s13023-019-1237-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
14 Bienaime F, Dragon-Durey MA, Regnier CH, Nilsson SC, Kwan WH, Blouin J, Jablonski M, Renault N, Rameix-Welti MA, Loirat C. Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int. 2010;77:339-349. [PMID: 20016463 DOI: 10.1038/ki.2009.472] [Cited by in Crossref: 121] [Cited by in F6Publishing: 108] [Article Influence: 9.3] [Reference Citation Analysis]
15 Fang CJ, Richards A, Liszewski MK, Kavanagh D, Atkinson JP. Advances in understanding of pathogenesis of aHUS and HELLP. British Journal of Haematology 2008;143:336-48. [DOI: 10.1111/j.1365-2141.2008.07324.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 56] [Article Influence: 5.1] [Reference Citation Analysis]
16 Johnson S, Taylor CM. Hemolytic Uremic Syndrome. In: Avner E, Harmon W, Niaudet P, Yoshikawa N, editors. Pediatric Nephrology. Berlin: Springer Berlin Heidelberg; 2009. pp. 1155-80. [DOI: 10.1007/978-3-540-76341-3_48] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Kavanagh D, Richards A, Fremeaux-Bacchi V, Noris M, Goodship T, Remuzzi G, Atkinson JP. Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2007;2:591-6. [PMID: 17699467 DOI: 10.2215/CJN.03270906] [Cited by in Crossref: 44] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
18 Shanmugalingam R, Hsu D, Makris A. Pregnancy-induced atypical haemolytic uremic syndrome: A new era with eculizumab. Obstet Med 2018;11:28-31. [PMID: 29636811 DOI: 10.1177/1753495X17704563] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
19 Cabrera JTO, Makino A. Efferocytosis of vascular cells in cardiovascular disease. Pharmacol Ther 2021;:107919. [PMID: 34171333 DOI: 10.1016/j.pharmthera.2021.107919] [Reference Citation Analysis]
20 Mayer CL, Leibowitz CS, Kurosawa S, Stearns-Kurosawa DJ. Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals. Toxins (Basel) 2012;4:1261-87. [PMID: 23202315 DOI: 10.3390/toxins4111261] [Cited by in Crossref: 86] [Cited by in F6Publishing: 68] [Article Influence: 8.6] [Reference Citation Analysis]
21 Liszewski MK, Atkinson JP. Complement regulator CD46: genetic variants and disease associations. Hum Genomics 2015;9:7. [PMID: 26054645 DOI: 10.1186/s40246-015-0029-z] [Cited by in Crossref: 61] [Cited by in F6Publishing: 48] [Article Influence: 8.7] [Reference Citation Analysis]
22 Yoshida H, Matsui H, Murayama SY, Takada Y, Matsuo K, Takahashi T, Nakamura M, Ubukata K, Takahashi T. A CD46 transgenic mouse model for studying the histopathology of arthritis caused by subcutaneous infection with Streptococcus dysgalactiae subspecies equisimilis. Journal of Medical Microbiology 2011;60:1860-8. [DOI: 10.1099/jmm.0.034108-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
23 Servais A, Frémeaux-Bacchi V, Lequintrec M, Salomon R, Blouin J, Knebelmann B, Grünfeld JP, Lesavre P, Noël LH, Fakhouri F. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 2007;44:193-9. [PMID: 17018561 DOI: 10.1136/jmg.2006.045328] [Cited by in Crossref: 211] [Cited by in F6Publishing: 187] [Article Influence: 13.2] [Reference Citation Analysis]
24 Salvadori M, Bertoni E. Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations. World J Nephrol 2013; 2(3): 56-76 [PMID: 24255888 DOI: 10.5527/wjn.v2.i3.56] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 44] [Article Influence: 7.1] [Reference Citation Analysis]
25 Frazer-abel A, Sepiashvili L, Mbughuni M, Willrich M. Overview of Laboratory Testing and Clinical Presentations of Complement Deficiencies and Dysregulation. Elsevier; 2016. pp. 1-75. [DOI: 10.1016/bs.acc.2016.06.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
26 Banda NK, Mehta G, Ferreira VP, Cortes C, Pickering MC, Pangburn MK, Arend WP, Holers VM. Essential role of surface-bound complement factor H in controlling immune complex-induced arthritis. J Immunol 2013;190:3560-9. [PMID: 23436934 DOI: 10.4049/jimmunol.1203271] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
27 Bao L, Wang Y, Chang A, Minto AW, Zhou J, Kang H, Haas M, Quigg RJ. Unrestricted C3 activation occurs in Crry-deficient kidneys and rapidly leads to chronic renal failure. J Am Soc Nephrol. 2007;18:811-822. [PMID: 17229915 DOI: 10.1681/asn.2006101176] [Cited by in Crossref: 39] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
28 Garam N, Cserhalmi M, Prohászka Z, Szilágyi Á, Veszeli N, Szabó E, Uzonyi B, Iliás A, Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G, Bajcsi D, Brunner J, Dumfarth A, Cejka D, Flaschberger S, Flögelova H, Haris Á, Hartmann Á, Heilos A, Mueller T, Rusai K, Arbeiter K, Hofer J, Jakab D, Sinkó M, Szigeti E, Bereczki C, Janko V, Kelen K, Reusz GS, Szabó AJ, Klenk N, Kóbor K, Kojc N, Knechtelsdorfer M, Laganovic M, Lungu AC, Meglic A, Rus R, Kersnik Levart T, Macioniene E, Miglinas M, Pawłowska A, Stompór T, Podracka L, Rudnicki M, Mayer G, Rysava R, Reiterova J, Saraga M, Seeman T, Zieg J, Sládková E, Stajic N, Szabó T, Capitanescu A, Stancu S, Tisljar M, Galesic K, Tislér A, Vainumäe I, Windpessl M, Zaoral T, Zlatanova G, Józsi M, Csuka D. FHR-5 Serum Levels and CFHR5 Genetic Variations in Patients With Immune Complex-Mediated Membranoproliferative Glomerulonephritis and C3-Glomerulopathy. Front Immunol 2021;12:720183. [PMID: 34566977 DOI: 10.3389/fimmu.2021.720183] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Mele C, Remuzzi G, Noris M. Hemolytic uremic syndrome. Semin Immunopathol 2014;36:399-420. [PMID: 24526222 DOI: 10.1007/s00281-014-0416-x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 67] [Article Influence: 11.5] [Reference Citation Analysis]
30 Watt T, Warshaw B, Katzenstein HM. Atypical hemolytic uremic syndrome responsive to steroids and intravenous immune globulin. Pediatr Blood Cancer 2009;53:90-1. [DOI: 10.1002/pbc.21951] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
31 Liszewski MK, Java A, Schramm EC, Atkinson JP. Complement Dysregulation and Disease: Insights from Contemporary Genetics. Annu Rev Pathol. 2017;12:25-52. [PMID: 27959629 DOI: 10.1146/annurev-pathol-012615-044145] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
32 Basnayake BMDB, Wazil AWM, Nanayakkara N, Samarakoon SMDK, Senavirathne EMSK, Thangarajah BUEWDR, Karunasena N, Mahanama RMBSS. Atypical hemolytic uremic syndrome: a case report. J Med Case Rep 2020;14:11. [PMID: 31928535 DOI: 10.1186/s13256-019-2334-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Kerr H, Richards A. Complement-mediated injury and protection of endothelium: lessons from atypical haemolytic uraemic syndrome. Immunobiology 2012;217:195-203. [PMID: 21855165 DOI: 10.1016/j.imbio.2011.07.028] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
34 Saland JM, Shneider BL, Bromberg JS, Shi PA, Ward SC, Magid MS, Benchimol C, Seikaly MG, Emre SH, Bresin E, Remuzzi G. Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2009;4:201-206. [PMID: 19005013 DOI: 10.2215/cjn.02170508] [Cited by in Crossref: 53] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
35 Liszewski MK, Leung MK, Schraml B, Goodship TH, Atkinson JP. Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndrome. Mol Immunol 2007;44:1559-68. [PMID: 17027083 DOI: 10.1016/j.molimm.2006.08.024] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
36 Salameh H, Abu Omar M, Alhariri A, Kisra S, Qasem A, Abdulhak AB. Adult Post-Kidney Transplant Familial Atypical Hemolytic Uremic Syndrome Successfully Treated With Eculizumab: A Case Report and Literature Review. Am J Ther 2016;23:e1110-5. [PMID: 25486517 DOI: 10.1097/MJT.0000000000000133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
37 Liszewski MK, Atkinson JP. Too Much of a Good Thing at the Site of Tissue Injury: The Instructive Example of the Complement System Predisposing to Thrombotic Microangiopathy. Hematology 2011;2011:9-14. [DOI: 10.1182/asheducation-2011.1.9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
38 Sridharan M, Go RS, Abraham RS, Fervenza FC, Sethi S, Bryant SC, Spears GM, Murray DL, Willrich MAV. Diagnostic Utility of Complement Serology for Atypical Hemolytic Uremic Syndrome. Mayo Clin Proc 2018;93:1351-62. [PMID: 30286829 DOI: 10.1016/j.mayocp.2018.07.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
39 Bu F, Borsa N, Gianluigi A, Smith RJ. Familial atypical hemolytic uremic syndrome: a review of its genetic and clinical aspects. Clin Dev Immunol 2012;2012:370426. [PMID: 23251215 DOI: 10.1155/2012/370426] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
40 Okroj M, Heinegård D, Holmdahl R, Blom AM. Rheumatoid arthritis and the complement system. Annals of Medicine 2009;39:517-30. [DOI: 10.1080/07853890701477546] [Cited by in Crossref: 113] [Cited by in F6Publishing: 105] [Article Influence: 8.7] [Reference Citation Analysis]
41 Kavanagh D, Pappworth IY, Anderson H, Hayes CM, Moore I, Hunze EM, Bennaceur K, Roversi P, Lea S, Strain L. Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon? Clin J Am Soc Nephrol. 2012;7:417-426. [PMID: 22223611 DOI: 10.2215/cjn.05750611] [Cited by in Crossref: 38] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
42 Nilsson SC, Kalchishkova N, Trouw LA, Fremeaux-Bacchi V, Villoutreix BO, Blom AM. Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor I. Eur J Immunol 2010;40:172-85. [PMID: 19877009 DOI: 10.1002/eji.200939280] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 3.8] [Reference Citation Analysis]
43 Sartain SE, Turner NA, Moake JL. TNF Regulates Essential Alternative Complement Pathway Components and Impairs Activation of Protein C in Human Glomerular Endothelial Cells. J I 2016;196:832-45. [DOI: 10.4049/jimmunol.1500960] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
44 Kavanagh D, Goodship T. Genetics and complement in atypical HUS. Pediatr Nephrol 2010;25:2431-42. [PMID: 20526633 DOI: 10.1007/s00467-010-1555-5] [Cited by in Crossref: 117] [Cited by in F6Publishing: 98] [Article Influence: 9.8] [Reference Citation Analysis]
45 Liszewski MK, Leung MK, Hauhart R, Fang CJ, Bertram P, Atkinson JP. Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity. J Immunol 2009;183:3150-9. [PMID: 19667083 DOI: 10.4049/jimmunol.0901366] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
46 Mittal N, Hartemayer R, Jandeska S, Giordano L. Steroid Responsive Atypical Hemolytic Uremic Syndrome Triggered by Influenza B Infection. J Pediatr Hematol Oncol 2019;41:e63-7. [PMID: 29702545 DOI: 10.1097/MPH.0000000000001180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
47 Fremeaux-Bacchi V, Sanlaville D, Menouer S, Blouin J, Dragon-Durey MA, Fischbach M, Vekemans M, Fridman WH. Unusual clinical severity of complement membrane cofactor protein-associated hemolytic-uremic syndrome and uniparental isodisomy. Am J Kidney Dis 2007;49:323-9. [PMID: 17261436 DOI: 10.1053/j.ajkd.2006.10.022] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
48 Phillips EH, Westwood JP, Brocklebank V, Wong EK, Tellez JO, Marchbank KJ, McGuckin S, Gale DP, Connolly J, Goodship TH, Kavanagh D, Scully MA. The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies. J Thromb Haemost 2016;14:175-85. [PMID: 26559391 DOI: 10.1111/jth.13189] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
49 Wong EKS, Kavanagh D. Diseases of complement dysregulation-an overview. Semin Immunopathol 2018;40:49-64. [PMID: 29327071 DOI: 10.1007/s00281-017-0663-8] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
50 Knoop M, Haller H, Menne J. [Human genetics in atypical hemolytic uremic syndrome-its role in diagnosis and treatment]. Internist (Berl) 2018;59:799-804. [PMID: 29995248 DOI: 10.1007/s00108-018-0455-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
51 Heuser CC, Eller AG, Warren J, Branch DW, Salmon J, Silver RM. A case-control study of membrane cofactor protein mutations in two populations of patients with early pregnancy loss. J Reprod Immunol 2011;91:71-5. [PMID: 21840606 DOI: 10.1016/j.jri.2011.05.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
52 Roumenina LT, Loirat C, Dragon-Durey MA, Halbwachs-Mecarelli L, Sautes-Fridman C, Fremeaux-Bacchi V. Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods. 2011;365:8-26. [PMID: 21215749 DOI: 10.1016/j.jim.2010.12.020] [Cited by in Crossref: 108] [Cited by in F6Publishing: 100] [Article Influence: 9.8] [Reference Citation Analysis]
53 Berger SP, Daha MR. Complement in glomerular injury. Semin Immunopathol 2007;29:375-84. [PMID: 17901956 DOI: 10.1007/s00281-007-0090-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
54 Forbes TA, Bradbury MG, Goodship TH, McKiernan PJ, Milford DV. Changing strategies for organ transplantation in atypical haemolytic uraemic syndrome: a tertiary case series. Pediatr Transplant 2013;17:E93-9. [PMID: 23461281 DOI: 10.1111/petr.12066] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
55 Khandelwal P, Birla S, Bhatia D, Puraswani M, Saini H, Sinha A, Hari P, Sharma A, Bagga A. Mutations in membrane cofactor protein (CD46) gene in Indian children with hemolytic uremic syndrome. Clin Kidney J 2018;11:198-203. [PMID: 29644059 DOI: 10.1093/ckj/sfx078] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
56 Kavanagh D, Goodship TH. Update on evaluating complement in hemolytic uremic syndrome. Curr Opin Nephrol Hypertens. 2007;16:565-571. [PMID: 18089972 DOI: 10.1097/mnh.0b013e3282f0872f] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
57 Piras R, Iatropoulos P, Bresin E, Todeschini M, Gastoldi S, Valoti E, Alberti M, Mele C, Galbusera M, Cuccarolo P, Benigni A, Remuzzi G, Noris M. Molecular Studies and an ex vivo Complement Assay on Endothelium Highlight the Genetic Complexity of Atypical Hemolytic Uremic Syndrome: The Case of a Pedigree With a Null CD46 Variant. Front Med (Lausanne) 2020;7:579418. [PMID: 33224962 DOI: 10.3389/fmed.2020.579418] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Bordron A, Bagacean C, Tempescul A, Berthou C, Bettacchioli E, Hillion S, Renaudineau Y. Complement System: a Neglected Pathway in Immunotherapy. Clin Rev Allergy Immunol 2020;58:155-71. [PMID: 31144209 DOI: 10.1007/s12016-019-08741-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
59 Rosales A, Riedl M, Zimmerhackl LB. Thrombotic microangiopathy: atypical HUS: current diagnostic and therapeutic approaches. Nat Rev Nephrol 2010;6:504-6. [PMID: 20736981 DOI: 10.1038/nrneph.2010.98] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
60 Kavanagh D, Goodship TH. Atypical hemolytic uremic syndrome: . Current Opinion in Hematology 2010;17:432-8. [DOI: 10.1097/moh.0b013e32833cae86] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
61 Wong EK, Goodship TH, Kavanagh D. Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol 2013;56:199-212. [PMID: 23810412 DOI: 10.1016/j.molimm.2013.05.224] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 6.7] [Reference Citation Analysis]
62 Fakhouri F, Frémeaux-bacchi V. Does hemolytic uremic syndrome differ from thrombotic thrombocytopenic purpura? Nat Rev Nephrol 2007;3:679-87. [DOI: 10.1038/ncpneph0670] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
63 Jönsen A, Nilsson SC, Ahlqvist E, Svenungsson E, Gunnarsson I, Eriksson KG, Bengtsson A, Zickert A, Eloranta ML, Truedsson L, Rönnblom L, Nordmark G, Sturfelt G, Blom AM. Mutations in genes encoding complement inhibitors CD46 and CFH affect the age at nephritis onset in patients with systemic lupus erythematosus. Arthritis Res Ther 2011;13:R206. [PMID: 22171659 DOI: 10.1186/ar3539] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
64 Bhatia D, Khandelwal P, Sinha A, Hari P, Cheong HI, Bagga A. Incomplete penetrance of CD46 mutation causing familial atypical hemolytic uremic syndrome. Pediatr Nephrol 2015;30:2215-20. [DOI: 10.1007/s00467-015-3189-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
65 Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol. 2013;33:508-530. [PMID: 24161037 DOI: 10.1016/j.semnephrol.2013.08.003] [Cited by in Crossref: 204] [Cited by in F6Publishing: 156] [Article Influence: 25.5] [Reference Citation Analysis]
66 Fields MA, Cai H, Bowrey HE, Moreira EF, Beck Gooz M, Kunchithapautham K, Gong J, Vought E, Del Priore LV. Nitrite Modification of Extracellular Matrix Alters CD46 Expression and VEGF Release in Human Retinal Pigment Epithelium. Invest Ophthalmol Vis Sci 2015;56:4231-8. [PMID: 26161984 DOI: 10.1167/iovs.15-16438] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
67 Leban N, Aloui S, Touati D, Lakhdhar R, Skhiri H, Lefranc G, Achour A, Elmay M, Lopez-Trascasa M, Sanchez-Corral P, Chibani J, Haj Khelil A. Atypical hemolytic uremic syndrome in the Tunisian population. Int Urol Nephrol 2011;43:559-64. [PMID: 20499172 DOI: 10.1007/s11255-010-9754-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
68 Le Quintrec M, Zuber J, Moulin B, Kamar N, Jablonski M, Lionet A, Chatelet V, Mousson C, Mourad G, Bridoux F. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant. 2013;13:663-675. [PMID: 23356914 DOI: 10.1111/ajt.12077] [Cited by in Crossref: 153] [Cited by in F6Publishing: 139] [Article Influence: 17.0] [Reference Citation Analysis]
69 Nester CM, Barbour T, de Cordoba SR, Dragon-Durey MA, Fremeaux-Bacchi V, Goodship TH, Kavanagh D, Noris M, Pickering M, Sanchez-Corral P. Atypical aHUS: State of the art. Mol Immunol. 2015;67:31-42. [PMID: 25843230 DOI: 10.1016/j.molimm.2015.03.246] [Cited by in Crossref: 162] [Cited by in F6Publishing: 136] [Article Influence: 23.1] [Reference Citation Analysis]
70 Liszewski MK, Fang CJ, Atkinson JP. Inhibiting complement activation on cells at the step of C3 cleavage. Vaccine 2008;26 Suppl 8:I22-7. [PMID: 19388160 DOI: 10.1016/j.vaccine.2008.11.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
71 Angioi A, Fervenza FC, Sethi S, Zhang Y, Smith RJ, Murray D, Van Praet J, Pani A, De Vriese AS. Diagnosis of complement alternative pathway disorders. Kidney International 2016;89:278-88. [DOI: 10.1016/j.kint.2015.12.003] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
72 Thomas MR, Robinson S, Scully MA. How we manage thrombotic microangiopathies in pregnancy. Br J Haematol 2016;173:821-30. [DOI: 10.1111/bjh.14045] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
73 Levi C, Frémeaux-bacchi V, Zuber J, Rabant M, Devriese M, Snanoudj R, Scemla A, Amrouche L, Mejean A, Legendre C, Sberro-soussan R. Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence. Transplantation 2017;101:2924-30. [DOI: 10.1097/tp.0000000000001909] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 3.4] [Reference Citation Analysis]
74 Matsukuma E, Imamura A, Iwata Y, Takeuchi T, Yoshida Y, Fujimura Y, Fan X, Miyata T, Kuwahara T. Postoperative atypical hemolytic uremic syndrome associated with complement c3 mutation. Case Rep Nephrol 2014;2014:784943. [PMID: 25431709 DOI: 10.1155/2014/784943] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
75 Reid VL, Mullan A, Erwig LP. Rapid recovery of membrane cofactor protein (MCP; CD46) associated atypical haemolytic uraemic syndrome with plasma exchange. BMJ Case Rep 2013;2013:bcr2013200980. [PMID: 24005975 DOI: 10.1136/bcr-2013-200980] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
76 Martínez-Barricarte R, Heurich M, Valdes-Cañedo F, Vazquez-Martul E, Torreira E, Montes T, Tortajada A, Pinto S, Lopez-Trascasa M, Morgan BP, Llorca O, Harris CL, Rodríguez de Córdoba S. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 2010;120:3702-12. [PMID: 20852386 DOI: 10.1172/JCI43343] [Cited by in Crossref: 163] [Cited by in F6Publishing: 83] [Article Influence: 13.6] [Reference Citation Analysis]
77 Atkinson JP, Goodship TH. Complement factor H and the hemolytic uremic syndrome. J Exp Med 2007;204:1245-8. [PMID: 17548524 DOI: 10.1084/jem.20070664] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 3.9] [Reference Citation Analysis]
78 Taylor CM, Machin S, Wigmore SJ, Goodship TH; working party from the Renal Association, the British Committee for Standards in Haematology and the British Transplantation Society. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol 2010;148:37-47. [PMID: 19821824 DOI: 10.1111/j.1365-2141.2009.07916.x] [Cited by in Crossref: 149] [Cited by in F6Publishing: 113] [Article Influence: 11.5] [Reference Citation Analysis]
79 Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, Pinto S, Goodship TH, Alberti M, Ribes D. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol. 2013;24:475-486. [PMID: 23431077 DOI: 10.1681/asn.2012090884] [Cited by in Crossref: 231] [Cited by in F6Publishing: 110] [Article Influence: 25.7] [Reference Citation Analysis]
80 Wong EK, Kavanagh D. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Transl Res 2015;165:306-20. [PMID: 25468487 DOI: 10.1016/j.trsl.2014.10.010] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 7.3] [Reference Citation Analysis]
81 Loirat C, Fremeaux-bacchi V. Recurrence of haemolytic uraemic syndrome after renal transplantation. Current Opinion in Organ Transplantation 2007;12:496-502. [DOI: 10.1097/mot.0b013e3282ef3d64] [Reference Citation Analysis]
82 Bruel A, Kavanagh D, Noris M, Delmas Y, Wong EKS, Bresin E, Provôt F, Brocklebank V, Mele C, Remuzzi G, Loirat C, Frémeaux-Bacchi V, Fakhouri F. Hemolytic Uremic Syndrome in Pregnancy and Postpartum. Clin J Am Soc Nephrol 2017;12:1237-47. [PMID: 28596415 DOI: 10.2215/CJN.00280117] [Cited by in Crossref: 86] [Cited by in F6Publishing: 37] [Article Influence: 17.2] [Reference Citation Analysis]
83 Li Q, Nacion K, Bu H, Lin F. Mouse CD4+ CD25+ T regulatory cells are protected from autologous complement mediated injury by Crry and CD59. Biochem Biophys Res Commun 2009;382:223-6. [PMID: 19281793 DOI: 10.1016/j.bbrc.2009.03.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
84 Rossio R, Lotta LA, Pontiggia S, Borsa NG, Garagiola I, Ardissino G, Mikovic D, Cugno M, Peyvandi F. A novel CD46 mutation in a patient with microangiopathy clinically resembling thrombotic thrombocytopenic purpura and normal ADAMTS13 activity. Haematologica 2015;100:e87-9. [PMID: 25381125 DOI: 10.3324/haematol.2014.111062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
85 Kavanagh D, Richards A, Noris M, Hauhart R, Liszewski MK, Karpman D, Goodship JA, Fremeaux-Bacchi V, Remuzzi G, Goodship TH, Atkinson JP. Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol 2008;45:95-105. [PMID: 17597211 DOI: 10.1016/j.molimm.2007.05.004] [Cited by in Crossref: 102] [Cited by in F6Publishing: 93] [Article Influence: 6.8] [Reference Citation Analysis]
86 Fang CJ, Fremeaux-Bacchi V, Liszewski MK, Pianetti G, Noris M, Goodship TH, Atkinson JP. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood 2008;111:624-32. [PMID: 17914026 DOI: 10.1182/blood-2007-04-084533] [Cited by in Crossref: 102] [Cited by in F6Publishing: 93] [Article Influence: 6.8] [Reference Citation Analysis]
87 Mollnes TE, Jokiranta TS, Truedsson L, Nilsson B, Rodriguez de Cordoba S, Kirschfink M. Complement analysis in the 21st century. Molecular Immunology 2007;44:3838-49. [DOI: 10.1016/j.molimm.2007.06.150] [Cited by in Crossref: 103] [Cited by in F6Publishing: 80] [Article Influence: 6.9] [Reference Citation Analysis]
88 Cao M, Ferreiro T, Leite BN, Pita F, Bolaños L, Valdés F, Alonso A, Vázquez E, Mosquera J, Trigás M, Rodríguez S. Two cases of atypical hemolytic uremic syndrome (aHUS) and eosinophilic granulomatosis with polyangiitis (EGPA): a possible relationship. CEN Case Rep 2017;6:91-7. [PMID: 28509134 DOI: 10.1007/s13730-017-0251-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
89 Couzi L, Contin-Bordes C, Marliot F, Sarrat A, Grimal P, Moreau JF, Merville P, Fremeaux-Bacchi V. Inherited deficiency of membrane cofactor protein expression and varying manifestations of recurrent atypical hemolytic uremic syndrome in a sibling pair. Am J Kidney Dis 2008;52:e5-9. [PMID: 18514989 DOI: 10.1053/j.ajkd.2008.02.359] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
90 Nunius C, Büttner-Herold M, Bertz S, Schiffer M, Buchholz B. Isolated thrombotic microangiopathy of the small intestine in a patient with atypical hemolytic uremic syndrome - a case report. BMC Nephrol 2020;21:104. [PMID: 32204691 DOI: 10.1186/s12882-020-01766-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]